/ /

  • linkedin
  • Increase Font
  • Sharebar

    ARMOR surveillance data update shows increased levels of resistance

    Continued monitoring of antibiotic susceptibility warranted as bacterial pathogens continue growth

    Take-home: The latest surveillance data on antibiotic resistance trends show increased levels of resistance among certain isolates, warranting ongoing, prospective, multicenter surveillance studies.

    Lake Villa, IL—The most recent surveillance data on antibiotic resistance trends show increased levels of drug resistance among Staphylococcus aureus and coagulase-negative staphylococci (CoNS) as well as among isolates of Pseudomonas aeruginosa in test sites across the United States.

    Results to date from 2013 were compared with those from 2012 by researchers from Bausch + Lomb. They also reported the first data from clinical sites in Canada.

    The Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study was initiated in the United States in 2009 to monitor resistance trends among bacterial pathogens of ocular significance. Sites in Canada have also begun participating in the study, and the 2012 to 2013 results will provide baseline data.

    To date, 239 isolates from 27 U.S. sites have been subjected to antibiotic susceptibility testing. Broth microdilution susceptibility testing per Clinical and Laboratory Standard Institute methods was performed for up to 16 representative antibiotics. Surveillance results showed that isolates of S. aureus and CoNS were non-susceptible to oxacillin/methicillin (43% to 59%), ciprofloxacin (33% to 43%), clindamycin (21%), and azithromycin (60% to 63%), a slight increase over the previous year. Multi-drug resistance (≥3 drug classes) remained prevalent in S. aureus and CoNS isolates (38% to 39%), especially among methicillin-resistant staphylococci (60% to 81%).

    “Although no antibiotics are approved for endophthalmitis prophylaxis, what most surgeons care about is what options are available that can protect our patients from this devastating eye infection,” said Mitchell Jackson, MD, founder and medical director of Jacksoneye, Lake Villa, IL.

    Surveillance study findings

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results